Literature DB >> 1381702

Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

P G Natali1, M R Nicotra, A B Winkler, R Cavaliere, A Bigotti, A Ullrich.   

Abstract

Mutations at the white spotting (w) locus in mice have deleterious effects on germ cells, melanocytes and hematopoietic stem cells. The w locus encodes the c-kit tyrosine-kinase receptor whose ligand is the product of the SI locus. Using monoclonal antibodies (MAb(s)) to the extracellular domain, we have evaluated the expression of c-kit in normal and transformed melanocytes. This cell lineage synthesizes a receptor with a mw of 145 kDa. The gene product is expressed in epidermal melanocytes and in a fraction of nevocytic and blue nevi. In primary melanomas, loss of the receptor is observed in more invasive lesions. Only 30% of the metastatic lesions express detectable levels of the receptor. These findings demonstrate that the c-kit product is down-regulated in melanocytes following malignant transformation. The functional relevance of this modulation remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381702     DOI: 10.1002/ijc.2910520207

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  47 in total

1.  Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.

Authors:  M Luca; S Huang; J E Gershenwald; R K Singh; R Reich; M Bar-Eli
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.

Authors:  Nicolas Penel; Corinne Delcambre; Xavier Durando; Stéphanie Clisant; Mohamed Hebbar; Sylvie Negrier; Charles Fournier; Nicolas Isambert; Frédéric Mascarelli; Frédéric Mouriaux
Journal:  Invest New Drugs       Date:  2008-06-13       Impact factor: 3.850

Review 3.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Authors:  James V Neiswender; Robert L Kortum; Caitlin Bourque; Melissa Kasheta; Leonard I Zon; Deborah K Morrison; Craig J Ceol
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

5.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

Review 6.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium.

Authors:  Chang Dae Ko; Jee Soo Kim; Byung Gyun Ko; Byung Ho Son; Hee Joon Kang; Ho Sung Yoon; Eun Yoon Cho; Gyungyub Gong; Sei Hyun Ahn
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

9.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 10.  The biology and management of uveal melanoma.

Authors:  Takami Sato; Fei Han; Akira Yamamoto
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.